Related Experiment Video

Updated: Aug 8, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

[Platelet inhibitors from a cardiological viewpoint: evidence based therapy and new concepts for the acute coronary

B T Ivandic1, E Giannitsis

  • 1Innere Medizin, Abt. III, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg.

Hamostaseologie
|May 6, 2006
PubMed

Insights

Platelet inhibitors are crucial for treating acute coronary syndromes by preventing clot formation. Recent advancements offer new strategies and drugs, addressing challenges like drug resistance in cardiology.

Area of Science:

  • Cardiology
  • Pharmacology
  • Inflammation Biology

Context:

  • Acute coronary syndrome (ACS) involves vulnerable plaques triggering platelet activation and aggregation.
  • Platelet inhibition is a cornerstone therapy for ACS management.
  • Current treatment guidelines are frequently updated due to rapid advancements.

Purpose:

  • To provide a cardiological perspective on clinical aspects and new developments in platelet inhibitors for ACS.
  • To highlight progress in antiplatelet therapy, including novel drugs and strategies.
  • To discuss challenges such as drug resistance associated with existing platelet inhibitors.

Summary:

  • The pathophysiology of ACS is linked to inflammatory plaques that promote platelet activation and aggregation.
  • Inhibiting platelet function is a primary therapeutic goal in ACS.
  • Recent years have seen significant progress, including new drug regimens, therapeutic strategies, and innovative pharmacological principles, with some novel agents undergoing clinical trials.
  • Increasing experience with current platelet inhibitors has identified shortcomings like drug resistance.

Impact:

  • This review offers insights into emerging antiplatelet therapies for ACS.
  • It addresses the clinical relevance of new developments and potential challenges in platelet inhibition.
  • The information is valuable for cardiologists and researchers seeking to optimize ACS treatment strategies.

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...